Second-Phase Hepatitis C Virus RNA Decline During Telaprevir-Based Therapy Increases With Drug Effectiveness: Implications for Treatment DurationGUEDJ, Jeremie; PERELSON, Alan S.Hepatology (Baltimore, Md.). 2011, Vol 53, Num 6, pp 1801-1808, issn 0270-9139, 8 p.Article

Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?SORIANO, Vincent; PERELSON, Alan S; ZOULIM, Fabien et al.Journal of antimicrobial chemotherapy (Print). 2008, Vol 62, Num 1, pp 1-4, issn 0305-7453, 4 p.Article

Multiplicity of human immunodeficiency virus infections in lymphoid tissueDIXIT, Narendra M; PERELSON, Alan S.Journal of virology. 2004, Vol 78, Num 16, pp 8942-8945, issn 0022-538X, 4 p.Article

Combination Antiviral Therapy for Influenza: Predictions From Modeling of Human InfectionsPERELSON, Alan S; LIBIN RONG; HAYDEN, Frederick G et al.The Journal of infectious diseases. 2012, Vol 205, Num 11, pp 1642-1645, issn 0022-1899, 4 p.Article

Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapyJONES, Laura E; PERELSON, Alan S.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 45, Num 5, pp 483-493, issn 1525-4135, 11 p.Article

Triphasic decline of hepatitis C virus RNA during antiviral therapyDAHARI, Harel; RIBEIRO, Ruy M; PERELSON, Alan S et al.Hepatology (Baltimore, Md.). 2007, Vol 46, Num 1, pp 16-21, issn 0270-9139, 6 p.Article

Dynamics of hepatitis B virus infectionRIBEIRO, Ruy M; LO, Arthur; PERELSON, Alan S et al.Microbes and infection. 2002, Vol 4, Num 8, pp 829-835, issn 1286-4579Article

Mathematical modelling of HCV infection: what can it teach us in the era of direct―acting antiviral agents?CHATTERJEE, Anushree; GUEDJ, Jeremie; PERELSON, Alan S et al.Antiviral therapy (London). 2012, Vol 17, Num 6, pp 1171-1182, issn 1359-6535, 12 p., bArticle

Modeling the effects of vaccination on chronically infected HIV-positive patientsJONES, Laura E; PERELSON, Alan S.Journal of acquired immune deficiency syndromes (1999). 2002, Vol 31, Num 4, pp 369-377, issn 1525-4135, 9 p.Article

On Identifiability of Nonlinear ODE Models and Applications in Viral DynamicsHONGYU MIAO; XIAOHUA XIA; PERELSON, Alan S et al.SIAM review (Print). 2011, Vol 53, Num 1, pp 3-39, issn 0036-1445, 37 p.Article

Modeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha InterferonDAHARI, Harel; SAINZ, Bruno; PERELSON, Alan S et al.Journal of virology. 2009, Vol 83, Num 13, pp 6383-6390, issn 0022-538X, 8 p.Article

Determining thymic output quantitatively : using models to interpret experimental T-cell receptor excision circle (TREC) dataRIBEIRO, Ruy M; PERELSON, Alan S.Immunological reviews. 2007, Vol 216, pp 21-34, issn 0105-2896, 14 p.Article

Modeling Complex Decay Profiles of Hepatitis B Virus During Antiviral TherapyDAHARI, Harel; SHUDO, Emi; RIBEIRO, Ruy M et al.Hepatology (Baltimore, Md.). 2009, Vol 49, Num 1, pp 32-38, issn 0270-9139, 7 p.Article

New kinetic models for the hepatitis C virusPERELSON, Alan S; HERRMANN, Eva; MICOL, Florence et al.Hepatology (Baltimore, Md.). 2005, Vol 42, Num 4, pp 749-754, issn 0270-9139, 6 p.Article

Optimization of influenza vaccine selectionWU, Joseph T; WEIN, Lawrence M; PERELSON, Alan S et al.Operations research. 2005, Vol 53, Num 3, pp 456-476, issn 0030-364X, 21 p.Article

Kinetics of virus-specific CD8⁺ T cells and the control of human immunodeficiency virus infectionDAVENPORT, Miles P; RIBEIRO, Ruy M; PERELSON, Alan S et al.Journal of virology. 2004, Vol 78, Num 18, pp 10096-10103, issn 0022-538X, 8 p.Article

Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of hiv viral dynamic parametersNELSON, Patrick W; MITTLER, John E; PERELSON, Alan S et al.Journal of acquired immune deficiency syndromes (1999). 2001, Vol 26, Num 5, pp 405-412, issn 1525-4135Article

Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decayDAHARI, Harel; SHUDO, Emi; COTLER, Scott J et al.Antiviral therapy (London). 2009, Vol 14, Num 3, pp 459-464, issn 1359-6535, 6 p.Article

Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapyMITTLER, John; ESSUNGER, Paulina; YUEN, Geoffrey J et al.Antimicrobial agents and chemotherapy. 2001, Vol 45, Num 5, pp 1438-1443, issn 0066-4804Article

Understanding silibinin's modes of action against HCV using viral kinetic modelingGUEDJ, Jeremie; DAHARI, Harel; POHL, Ralf T et al.Journal of hepatology. 2012, Vol 56, Num 5, pp 1019-1024, issn 0168-8278, 6 p.Article

Estimating division and death rates from CFSE dataDE BOER, Rob J; PERELSON, Alan S.Journal of computational and applied mathematics. 2005, Vol 184, Num 1, pp 140-164, issn 0377-0427, 25 p.Article

Mathematical modeling of subgenomic hepatitis C virus replication in huh-7 cellsDAHARI, Harel; RIBEIRO, Ruy M; RICE, Charles M et al.Journal of virology. 2007, Vol 81, Num 2, pp 750-760, issn 0022-538X, 11 p.Article

Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virusDAVENPORT, Miles P; RIBEIRO, Ruy M; CHAO, Dennis L et al.Journal of virology. 2004, Vol 78, Num 20, pp 11340-11351, issn 0022-538X, 12 p.Article

Retention of antigen on follicular dendritic cells and B lymphocytes through complement-mediated multivalent ligand-receptor interactions: Theory and application to HIV treatmentHLAVACEK, William S; PERCUS, Jerome K; PERCUS, Ora E et al.Mathematical biosciences. 2002, Vol 176, Num 2, pp 185-202, issn 0025-5564Article

Recombination increases human immunodeficiency virus fitness, but not necessarily diversityVIJAY, N. N. V; VASANTIKA; AJMANI, Rahul et al.Journal of general virology. 2008, Vol 89, pp 1467-1477, issn 0022-1317, 11 p., 6Article